Proposed directorate change

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Proposed directorate change

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that subject to the completion of normal regulatory due diligence, Sean Christie will be appointed as Non-Executive Director.

Sean has a wealth of international experience in the food, ingredient and chemical sectors as Finance Director of Northern Foods plc (1996-2004) and Croda plc (2006-2015), a FTSE 100 company. During this time, he was actively involved in M&A activity helping Croda to grow to a £1.4bn turnover operating in 36 countries. Sean left Croda in 2015 and has subsequently taken on a number of Board positions in both AIM listed and private companies.

Stephen O'Hara, CEO of OptiBiotix, commented: "I am delighted that Sean will join the Board. He brings a unique mix of sector specific financial, investor and M&A expertise and a strong track record of delivering revenue growth and creating shareholder value. His international network of contacts and wealth of experience on the Board of FTSE100 companies like Croda plc will help OptiBiotix build a substantive microbiome business across all its platforms. OptiBiotix is working in what is forecast to be one of the world's fastest growth areas and Sean's international sector specific expertise will help OptiBiotix continue to be one of the world's leaders in the exciting microbiome field.  We will continue to evolve the Board and management team as we extend the global reach of our products and in-line with the continued growth and expansion of the Company."

A further announcement will be made in due course.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.